In Alzheimer’s disease, ADAM10 activation has the potential to inhibit disease progression, because ADAM10 cleavage of amyloid precursor protein (APP) prevents the generation of the pathogenic amyloid β peptide, which can otherwise be produced by β- and γ-secretases cleaving at alternative sites [22]. Here, APP is linked to early-onset autosomal dominant Alzheimer disease.